Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13–26-Year-Old Young Men After HPV Vaccine Introduction

Emmanuel Chandler, Lili Ding, Pamina Gorbach, Eduardo L. Franco, Darron Brown, Lea E. Widdice, David I. Bernstein, Jessica A. Kahn

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: The aims of this study were to determine prevalence of and factors associated with any human papillomavirus (HPV) and vaccine-type HPV among young men after vaccine introduction, stratified by vaccination status. Methods: Young men were recruited from clinical sites from 2013 to 2015, completed a survey, and were tested for 36 anogenital HPV types. We determined factors associated with ≥1 HPV type among all participants, and vaccine-type HPV (HPV6, 11, 16, and/or 18) among all, vaccinated and unvaccinated participants, using multivariable regression. Results: Mean age was 21.5 years and 26% had received at least one HPV vaccine dose. HPV prevalence was lower in vaccinated versus unvaccinated young men (50.5% vs. 62.6%, p =.03). HPV positivity was discordant by anogenital site. At both sites, 59.4% were positive for ≥1 HPV type and 26.0% for ≥1 4-valent vaccine type. In multivariable logistic regression, factors associated with ≥1 HPV type among all participants were frequency of oral sex (odds ratio [OR] = 1.80, 95% confidence interval [CI] = 1.00–3.24), recent smoking (OR = 1.84, CI = 1.17–2.90), and sexually transmitted infection history (OR = 1.56, CI = 1.02–2.38). Factors associated with vaccine-type HPV among all participants were white versus black race (OR = 1.91, CI = 1.10–3.34) and gonorrhea history (OR = 2.52, CI = 1.45–4.38); among vaccinated participants were private versus Medicaid insurance (OR = 5.6, CI = 1.46–20.4) and private versus no insurance (OR = 15.9, CI = 3.06–83.3); and among unvaccinated participants was gonorrhea history (OR = 1.83, CI = 1.03–3.24). Conclusions: Anogenital HPV prevalence was high and vaccination rates low among young men 2–4 years after vaccine introduction, underscoring the urgency of increasing vaccination rates and vaccinating according to national guidelines.

Original languageEnglish (US)
Pages (from-to)43-49
Number of pages7
JournalJournal of Adolescent Health
Volume63
Issue number1
DOIs
StatePublished - Jul 1 2018

Fingerprint

Papillomavirus Vaccines
Epidemiology
Vaccines
Odds Ratio
Confidence Intervals
Vaccination
Gonorrhea
Insurance
Human papillomavirus 11
Sex Ratio
Medicaid
Sexually Transmitted Diseases
Sexual Behavior
Logistic Models
Smoking
Guidelines

Keywords

  • Human papillomavirus
  • Sexually transmitted infections
  • Vaccines
  • Young men

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Public Health, Environmental and Occupational Health
  • Psychiatry and Mental health

Cite this

Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13–26-Year-Old Young Men After HPV Vaccine Introduction. / Chandler, Emmanuel; Ding, Lili; Gorbach, Pamina; Franco, Eduardo L.; Brown, Darron; Widdice, Lea E.; Bernstein, David I.; Kahn, Jessica A.

In: Journal of Adolescent Health, Vol. 63, No. 1, 01.07.2018, p. 43-49.

Research output: Contribution to journalArticle

Chandler, Emmanuel ; Ding, Lili ; Gorbach, Pamina ; Franco, Eduardo L. ; Brown, Darron ; Widdice, Lea E. ; Bernstein, David I. ; Kahn, Jessica A. / Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13–26-Year-Old Young Men After HPV Vaccine Introduction. In: Journal of Adolescent Health. 2018 ; Vol. 63, No. 1. pp. 43-49.
@article{9a219959d1e541e9a518cf6a33c74eff,
title = "Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13–26-Year-Old Young Men After HPV Vaccine Introduction",
abstract = "Purpose: The aims of this study were to determine prevalence of and factors associated with any human papillomavirus (HPV) and vaccine-type HPV among young men after vaccine introduction, stratified by vaccination status. Methods: Young men were recruited from clinical sites from 2013 to 2015, completed a survey, and were tested for 36 anogenital HPV types. We determined factors associated with ≥1 HPV type among all participants, and vaccine-type HPV (HPV6, 11, 16, and/or 18) among all, vaccinated and unvaccinated participants, using multivariable regression. Results: Mean age was 21.5 years and 26{\%} had received at least one HPV vaccine dose. HPV prevalence was lower in vaccinated versus unvaccinated young men (50.5{\%} vs. 62.6{\%}, p =.03). HPV positivity was discordant by anogenital site. At both sites, 59.4{\%} were positive for ≥1 HPV type and 26.0{\%} for ≥1 4-valent vaccine type. In multivariable logistic regression, factors associated with ≥1 HPV type among all participants were frequency of oral sex (odds ratio [OR] = 1.80, 95{\%} confidence interval [CI] = 1.00–3.24), recent smoking (OR = 1.84, CI = 1.17–2.90), and sexually transmitted infection history (OR = 1.56, CI = 1.02–2.38). Factors associated with vaccine-type HPV among all participants were white versus black race (OR = 1.91, CI = 1.10–3.34) and gonorrhea history (OR = 2.52, CI = 1.45–4.38); among vaccinated participants were private versus Medicaid insurance (OR = 5.6, CI = 1.46–20.4) and private versus no insurance (OR = 15.9, CI = 3.06–83.3); and among unvaccinated participants was gonorrhea history (OR = 1.83, CI = 1.03–3.24). Conclusions: Anogenital HPV prevalence was high and vaccination rates low among young men 2–4 years after vaccine introduction, underscoring the urgency of increasing vaccination rates and vaccinating according to national guidelines.",
keywords = "Human papillomavirus, Sexually transmitted infections, Vaccines, Young men",
author = "Emmanuel Chandler and Lili Ding and Pamina Gorbach and Franco, {Eduardo L.} and Darron Brown and Widdice, {Lea E.} and Bernstein, {David I.} and Kahn, {Jessica A.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.jadohealth.2018.01.005",
language = "English (US)",
volume = "63",
pages = "43--49",
journal = "Journal of Adolescent Health",
issn = "1054-139X",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13–26-Year-Old Young Men After HPV Vaccine Introduction

AU - Chandler, Emmanuel

AU - Ding, Lili

AU - Gorbach, Pamina

AU - Franco, Eduardo L.

AU - Brown, Darron

AU - Widdice, Lea E.

AU - Bernstein, David I.

AU - Kahn, Jessica A.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Purpose: The aims of this study were to determine prevalence of and factors associated with any human papillomavirus (HPV) and vaccine-type HPV among young men after vaccine introduction, stratified by vaccination status. Methods: Young men were recruited from clinical sites from 2013 to 2015, completed a survey, and were tested for 36 anogenital HPV types. We determined factors associated with ≥1 HPV type among all participants, and vaccine-type HPV (HPV6, 11, 16, and/or 18) among all, vaccinated and unvaccinated participants, using multivariable regression. Results: Mean age was 21.5 years and 26% had received at least one HPV vaccine dose. HPV prevalence was lower in vaccinated versus unvaccinated young men (50.5% vs. 62.6%, p =.03). HPV positivity was discordant by anogenital site. At both sites, 59.4% were positive for ≥1 HPV type and 26.0% for ≥1 4-valent vaccine type. In multivariable logistic regression, factors associated with ≥1 HPV type among all participants were frequency of oral sex (odds ratio [OR] = 1.80, 95% confidence interval [CI] = 1.00–3.24), recent smoking (OR = 1.84, CI = 1.17–2.90), and sexually transmitted infection history (OR = 1.56, CI = 1.02–2.38). Factors associated with vaccine-type HPV among all participants were white versus black race (OR = 1.91, CI = 1.10–3.34) and gonorrhea history (OR = 2.52, CI = 1.45–4.38); among vaccinated participants were private versus Medicaid insurance (OR = 5.6, CI = 1.46–20.4) and private versus no insurance (OR = 15.9, CI = 3.06–83.3); and among unvaccinated participants was gonorrhea history (OR = 1.83, CI = 1.03–3.24). Conclusions: Anogenital HPV prevalence was high and vaccination rates low among young men 2–4 years after vaccine introduction, underscoring the urgency of increasing vaccination rates and vaccinating according to national guidelines.

AB - Purpose: The aims of this study were to determine prevalence of and factors associated with any human papillomavirus (HPV) and vaccine-type HPV among young men after vaccine introduction, stratified by vaccination status. Methods: Young men were recruited from clinical sites from 2013 to 2015, completed a survey, and were tested for 36 anogenital HPV types. We determined factors associated with ≥1 HPV type among all participants, and vaccine-type HPV (HPV6, 11, 16, and/or 18) among all, vaccinated and unvaccinated participants, using multivariable regression. Results: Mean age was 21.5 years and 26% had received at least one HPV vaccine dose. HPV prevalence was lower in vaccinated versus unvaccinated young men (50.5% vs. 62.6%, p =.03). HPV positivity was discordant by anogenital site. At both sites, 59.4% were positive for ≥1 HPV type and 26.0% for ≥1 4-valent vaccine type. In multivariable logistic regression, factors associated with ≥1 HPV type among all participants were frequency of oral sex (odds ratio [OR] = 1.80, 95% confidence interval [CI] = 1.00–3.24), recent smoking (OR = 1.84, CI = 1.17–2.90), and sexually transmitted infection history (OR = 1.56, CI = 1.02–2.38). Factors associated with vaccine-type HPV among all participants were white versus black race (OR = 1.91, CI = 1.10–3.34) and gonorrhea history (OR = 2.52, CI = 1.45–4.38); among vaccinated participants were private versus Medicaid insurance (OR = 5.6, CI = 1.46–20.4) and private versus no insurance (OR = 15.9, CI = 3.06–83.3); and among unvaccinated participants was gonorrhea history (OR = 1.83, CI = 1.03–3.24). Conclusions: Anogenital HPV prevalence was high and vaccination rates low among young men 2–4 years after vaccine introduction, underscoring the urgency of increasing vaccination rates and vaccinating according to national guidelines.

KW - Human papillomavirus

KW - Sexually transmitted infections

KW - Vaccines

KW - Young men

UR - http://www.scopus.com/inward/record.url?scp=85050470767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050470767&partnerID=8YFLogxK

U2 - 10.1016/j.jadohealth.2018.01.005

DO - 10.1016/j.jadohealth.2018.01.005

M3 - Article

VL - 63

SP - 43

EP - 49

JO - Journal of Adolescent Health

JF - Journal of Adolescent Health

SN - 1054-139X

IS - 1

ER -